Title: *Neisseria meningitidis* carriage, antimicrobial resistance, and risk factors in UK men who have sex with men

Aminah Memon1, Manik Kohli2, Wenyu Liu1, Emmi Suonpera2, Yomna Gharib2, Christos Karathanasis2, Fowsiya Nur2, Richard Gilson2, Odile B Harrison*1

1. Nuffield Department of Population Health, University of Oxford, UK

2. Centre for Clinical Research in Infection & Sexual Health, UCL Institute for Global Health, Mortimer Market Centre, London, UK

*Corresponding author

Keywords: *Neisseria meningitidis*, genomics, oropharyngeal, antimicrobial resistance, men who have sex with men

Abstract

Urogenital infections caused by *Neisseria meningitidis* (Nm) are increasing globally, yet the prevalence, antimicrobial resistance profiles, and transmission dynamics of Nm in men who have sex with men (MSM) remain poorly defined. We conducted an oropharyngeal carriage study in 174 MSM attending a London sexual health clinic in 2023, prior to the implementation of 4CMenB vaccination and doxycycline post-exposure prophylaxis (doxyPEP). Nm was detected in 21.26% of participants, with carriage significantly associated with throat gonorrhoea, consistent with frequent co-colonisation. Whole-genome sequencing identified diverse lineages, including hyperinvasive clonal complexes (CC)11 and CC4821, and revealed widespread tetracycline resistance: 43% of isolates carried either a conjugative *tet(M)* plasmid or chromosomal *tet(B)* efflux locus. These findings indicate that MSM represent an important reservoir of tetracycline-resistant Nm, with the potential amplification of this phenotype following doxyPEP implementation, underscoring the need for genomic surveillance of *Neisseria* species in sexual networks.

Introduction

Neisseria meningitidis (the meningococcus, Nm) is an opportunistic Gram-negative bacterial pathogen that spreads through aerosol transmission and colonises the human oropharynx. While the meningococcus generally exists as an asymptomatic commensal in approximately 10% of healthy individuals [1], invasive meningococcal disease (IMD) can manifest rapidly in infants, children, teenagers, and immunocompromised individuals and, more recently, has been increasingly observed in men-who-have-sex-with-men (MSM) [2].

Nm oropharyngeal carriage is a prerequisite for IMD, with transmission of Nm from carriers to susceptible individuals linked to an increased incidence of disease [3]. Typically, Nm carriage is associated with teenagers and adolescents due to their high carriage rates and increased risk for IMD [4-6]. High rates, however, have been recorded in MSM [7-9] with IMD outbreaks, predominantly driven by serogroup C Nm (MenC) belonging to clonal complex CC11, frequently reported in this population [10-13]. Social behaviours, including attendance at pubs/clubs, intimate kissing, and cigarette smoking are strongly associated with increased risk for meningococcal carriage in UK teenagers [4]. Similarly, sexual and social behaviours promoting frequent close contact will increase the risk for Nm transmission and carriage in sexually active groups including young adults, and MSM, with additional factors potentially reducing immunity such as HIV status [7].

In the UK, there is, however, limited information on Nm oropharyngeal carriage rates in MSM or how frequently Nm co-colonises with *Neisseria gonorrhoeae* (the gonococcus, Ng), a leading cause of sexually transmitted infection (STI), that has developed extensive antimicrobial resistance (AMR) [14, 15]. MSM frequently experience recurrent *N. gonorrhoeae* infections, including oral gonorrhoea. Combined with the high *N. meningitidis* carriage rates observed in this group, this suggests that co-colonisation of the oropharynx by both species is common, creating opportunities for interspecies horizontal gene transfer (HGT). Indeed, Nm and Ng isolates containing genetic determinants originating from either species have been documented consistent with HGT and leading to evolutionary adaptive changes that facilitate

55 persistence in different anatomical niches, reduce susceptibility to antimicrobial treatment, or
56 hinder detection using molecular diagnostics [16, 17].

57 To curb rising numbers of Ng cases reported in the UK, many of which increasingly
58 antimicrobial resistant, the UK has introduced measures to prevent Ng infections, including
59 vaccination with the Nm outer membrane vesicle vaccine (OMV), 4CMenB. This has been
60 accompanied with the introduction of doxycycline post-exposure prophylaxis (doxyPEP) to
61 limit other bacterial STIs with both offered to at-risk groups including MSM [18, 19]. Given the
62 prevalence of Nm in MSM, these interventions will likely also affect Nm circulating in this
63 population. We therefore undertook a cross-sectional, pilot study in MSM attending a sexual
64 health clinic in central London, UK in 2023, pre-4CMenB and doxyPEP use, to assess
65 oropharyngeal carriage and characterise the *Neisseria* population present. We detected a
66 21.26% Nm carriage rate with several serogroup B (MenB), tetracycline, azithromycin,
67 ciprofloxacin, and penicillin resistant Nm found that had unknown predicted cross-reactivity
68 with 4CMenB. The introduction of 4CMenB vaccination combined with doxyPEP therefore
69 raises concerns on the selection and expansion of Nm exhibiting decreased antimicrobial
70 susceptibility and indicate that further carriage studies are needed to understand *Neisseria*
71 species dynamics, the incidence of Nm and Ng co-colonisation, and the potential impact of
72 4CMenB and doxyPEP on both Nm and Ng.

73

Results

Participant demographics, clinical NAATs results and *Neisseria* carriage rates

From May to September 2023, 174 MSM were recruited and provided oropharyngeal swabs from which 37 Gram negative, oxidase positive diplococci (GND+ve) were retrieved, all subsequently identified through whole genome sequencing as *N. meningitidis* (Nm) and resulting in a 21.26% (n = 37/174) carriage rate. Two samples were found to be mixed *N. meningitidis/N. gonorrhoeae* isolates.

No significant associations were found between Nm carriage and participant demographics (Table 1). Most participants were aged 25 to 54 with the highest number of participants in the 35-44 age range (55/174, 31.61%) closely followed by 25- to 34-year-olds (46/174, 26.44%) (Table 1). A total of 61 (35.06%) participants identified as white British with 48 (27.59%) identifying as white other background. Most participants reported living with one other person (86/174, 49.43%). The most frequent Nm carriers were aged 25 to 34 (12/37, 32.43%) with those aged 35 to 44 the most frequent non-Nm carriers (n = 47/137, 34.31%) (Table 1). Both carriers and non-carriers had similar proportions of partners (carriers: n = 35, 94.59%; non-carriers: n = 122, 89.05%).

Clinical NAAT results from the 37 GND+ve positive samples, found seven (18.9%) positive for throat gonorrhoea, six (16.22%) for rectal gonorrhoea, and two (5.41%) for urethral gonorrhoea. One sample was positive for throat and urethral chlamydia respectively (2.70%), and two (5.41%) for rectal chlamydia. None were positive for syphilis while two participants reported having a cold/sore throat at the time of the study. Among Nm negative samples (n = 137), 10 (7.30%) were NAATs positive for throat gonorrhoea, 14 (10.22%) for rectal gonorrhoea, five (3.65%) for urethral gonorrhoea, four (2.92%) for throat chlamydia, eight (5.84%) for urethral chlamydia, and five (3.65%) for rectal chlamydia. Seven (5.12%) were positive for syphilis and 13 (9.49%) reported a cold/sore throat.

100 Social, sexual, and clinical risk factors associated with Nm carriage

101 No causal variables were significantly associated with carriage after adjusting for confounders
102 although social and sexual behaviours promoting close contact generally had higher odds of
103 carriage (Figure 1). Smoking 11 to 20 cigarettes daily (aOR = 2.06, 95% CI: 0.40–8.73, *p* =
104 0.614) and waterpipe sharing (aOR = 4.18, 95% CI: 0.89–19.20, *p* = 0.186) experienced
105 increased odds. Frequent sexual activity with multiple partners increased odds of carriage
106 such as condomless anal sex three months prior to the study (aOR = 1.23, 95% CI: 0.44-4.02,
107 *p*-value = 0.701) and having three or more male partners three months prior to the study (aOR
108 = 1.96, 95% CI: 0.30-38.90, *p*-value = 0.295). Among non-causal exposures, a significant
109 association between taking PrEP and carriage was found (aOR = 2.56, 95% CI: 1.03-6.78, *p*-
110 value = 0.042) (Figure 2). Mutual masturbation (aOR = 1.90, 95% CI: 0.81-4.78, *p*-value =
111 0.140) experienced higher odds of carriage. Vaping, fisting someone, anal sex toy use, and
112 getting fisted had aOR <1 in the adjusted models.

113 A positive throat gonorrhoea NAAT result was significantly associated with Nm carriage
114 (OR = 2.96, 95% CI: 1.00-8.37, *p*-value = 0.049) with a positive urethral gonorrhoea NAAT
115 result also significantly increasing odds of Nm carriage (OR = 5.11, 95% CI: 1.45-1.78, *p*-value
116 = 0.012) (Table 2 & Figure 3). The throat and oropharynx are anatomical niches for both Nm
117 and Ng, with higher odds of Nm carriage associated with positive NAATs results likely
118 reflecting similar transmission pathways that are exploited by both pathogens, consistent with
119 co-colonisation. Lower odds ratios were observed for chlamydia NAAT results in association
120 with Nm carriage compared to gonorrhoea NAAT results, indicating that this was specific for
121 gonorrhoea. Odds ratios <1 were observed for HIV positive, a positive rectal chlamydia NAAT
122 result, and a cold/sore throat.

123 *N. meningitidis* Isolate Characterisation

124 Thirty-seven Gram negative diplococci were retrieved of which 35 were identified as Nm
125 (35/37, 94.59%). The remaining two isolates were mixed cultures, consisting of Nm and Ng,
126 indicative of co-colonisation and were not further analysed here.

127 A total of 24 MLST STs were identified including five novel STs (Table 3). The most prevalent
128 were ST-11 (5/35, 14.28%) and ST-5662 (5/35, 14.28%). Three isolates were ST-11563 (3/35,
129 8.57%), two isolates were ST-11312 and ST-5953 each (2/35, 5.71%), and 19 isolates
130 possessed unique STs, identified once in this study. Most isolates did not belong to a clonal
131 complex (CC) (n = 25/35, 71.42%). Of the 12 isolates that did, CC11 (5/35, 14.28%), CC4821
132 (3/35, 8.57%), CC198 (1/35, 2.85%), CC162 (1/35, 2.85%), and CC1136 (1/35, 2.85%) were
133 identified. MenB made up most isolates (12/35, 34.28%), followed by group Z (6/35, 17.14%),
134 MenW (4/35, 11.42%), and group X (1/35, 2.85%). Examination of the ST-5662 MenB isolates
135 revealed that ST-17927 (id: 150945) and ST-11563 (id: 150924) isolates belonged to the same
136 genome lineage and shared five of the seven MLST alleles indicative of an ST-5662 clonal
137 complex (Supplementary Figure 2A). Eleven isolates were capsule null (*cnl*) (11/35, 31.42%).
138 Three isolates (IDs: 150946, 150959 and 150935) (3/35, 8.57%) could not be assigned a
139 capsule group.

140 The five CC11 meningococci were MenW (n = 4) with a non-groupable isolate (n = 1).
141 The non-groupable isolate (150935, MSMCARR-045), NG: P1.5-1,10-8:F3-6:ST-11, was
142 predicted to have a non-functional capsule due to the presence of the IS1301 insertion
143 element in the capsule locus deleting the sialic acid biosynthesis genes *cssA*/*B*/*C* (NEIS0054-
144 NEIS0052) and part of the capsule polymerase gene *csc* (NEIS0051). This isolate possessed
145 alleles in the *norB-aniA* cassette (NEIS1546-NEIS1550), *ispD* (NEIS11438-NEIS1446), and
146 arginine biosynthesis (*argB*) operon (NEIS1037-NEIS1038) that were identical to Nm from the
147 urethritis clade, US_NmUC-A clade, first identified in the United States in 2015-2016 but
148 observed globally since [20]. The four MenW isolates possessed the strain designation: W:
149 P5,2: F1-1,ST-11 and belonged to the South American-United Kingdom MenW:CC11
150 sublineage responsible for MenW outbreaks in the United Kingdom and elsewhere beginning
151 in 2009 and leading to the implementation in UK routine immunisation schedules in 2015 of
152 the MenACWY polysaccharide-conjugate vaccine [21].

153 All Nm whole genome sequence data (WGS) were examined for antigen cross-
154 reactivity with Bexsero (4CMenB) and Trumenba (rLP2086) using the MenDeVAR Index and
155 the Bexsero antigen sequence typing (BAST) typing scheme [22, 23]. An *fHbp* gene was
156 present in all except one Nm isolate. Variant 2 peptides were the most prevalent, found in
157 29/35 (82.85%) isolates with peptides 18 (n = 10), 22 (n = 7) and 19 (n = 2) accounting for
158 19/35 (54.28%) of the collection (Table 3). Variant 1 peptides were found in 4/35 (11.42%) of
159 isolates with variant 3 found in two isolates. The *nhba* gene was present in all isolates with
160 five Nm harbouring *nhba* genes predicted to be non-functional due to the presence of
161 frameshift mutations resulting in premature stop codons. The *nadA* gene was absent in 30/35
162 (85.71%) isolates. A total of 22 BAST types were identified (Table 3). Of the 12 MenB isolates,
163 none had sufficient data to predict 4CMenB vaccine coverage using available experimental
164 data most likely due to fHbp and NHBA peptides for which no phenotypic data were available
165 to allow predictions. Predicted coverage with rLP2086 was however observed for five MenB
166 isolates, due to these possessing variant 2 fHbp peptides. Overall, four isolates (n = 5/35,
167 14.28%) were predicted to have antigens that were cross-reactive with 4CMenB, while 11
168 isolates were predicted to be cross-reactive with rLP2086 (n = 11/35, 31.42%).

169 Genotypic and phenotypic antimicrobial resistance

170 *Azithromycin*

171 Phenotypic results showed that one isolate (1/35, 2.85%) exhibited medium-level resistance
172 to azithromycin (16 mg/mL), six (6/35, 14.28%) low-level resistance (1-1.5 mg/mL) and seven
173 (7/35, 22.85%) intermediate-level resistance (0.25-0.94 mg/mL), with the remaining 21 (21/35,
174 60%) isolates susceptible (0.047-0.19 mg/mL) (Table 4). None of the isolates exhibiting
175 medium to low-level resistance (n = 13) possessed 23S rRNA mutations, however, they
176 possessed MtrD alleles with the following amino acid substitutions known to confer resistance:
177 (i) F854L (n = 1), (ii) K823E, F854L (n = 7), (iii) R714G; S821A; K823E; F854L (n = 1) and (iv)
178 S821A; K823E; F854L (n = 2). Five of these isolates also possessed MtrR alleles with amino
179 acid substitutions associated with resistance [24]. This included: (i) A39T; D79N (n = 1), (ii)

180 D79N; A86T; S183N (n = 3), H105Y; S183N (n = 1). Three isolates possessed *mtrR* alleles
181 lacking a stop codon. Allele 1216, found in one isolate (id 150923, B: P17-6, 23: F3-36: ST-
182 11311 (cc4821)), harboured a premature stop codon, resulting in a predicted non-functional
183 *mtrR*.

184 *Penicillin*

185 The majority of isolates (28/35, 80%) were categorised as penicillin-susceptible, increased
186 exposure (PenI, 0.094-0.25 mg/mL). Two isolates were found to be penicillin-susceptible,
187 standard exposure (PenS, MICs 0.032–0.047 mg/L). Five isolates were penicillin-resistant
188 (PenR, 5/35, 14.28%, 0.38-0.5 mg/mL). The amino acid substitutions F504L, A510V, I515V,
189 H541N, and I566V known to confer resistance to penicillin were identified in all PenI and PenR
190 isolates (n = 33/35, 94.28%) and in 10 distinct *penA* alleles. No *penA* alleles were identified
191 with the amino acid substitutions A311V, T483S, A501T, D511V, or G545S described in Ng
192 and associated with reduced susceptibility to third-generation cephalosporins. The plasmid-
193 borne beta-lactamase genes, bla_{ROB-1} (NEIS3240) and bla_{TEM-1} (NEIS2357), were absent in all
194 isolates. Likewise, none of the *ponA* (NEIS0414) alleles contained the L421P amino acid
195 mutation linked to penicillin resistance in Ng.

196 *Ciprofloxacin*

197 Nine (9/35, 25.71%; 0.125-0.5 mg/mL) isolates were resistant to ciprofloxacin. The remaining
198 24 isolates were susceptible (24/35, 68.57%; 0.002-0.008 mg/mL). Genotypic resistance was
199 associated with the T91I substitution. None of the isolates harboured D95G/A/N/Y or T173N
200 mutations in *gyrA* found in Ng. The amino acid substitution, S87R, in *parC* (NEIS1525)
201 associated with increased ciprofloxacin resistance was identified in one isolate (n = 1/35,
202 2.85%), allele 243.

203 *Tetracycline resistance*

204 Fifteen isolates exhibited tetracycline resistance (15/35, 42.85%; 4-48 mg/mL). The remaining
205 20 isolates were categorised as susceptible (20/35, 57.14%; 0.19-1 mg/mL). One isolate (ID:

206 150969 Z: P22, 14-6: F3-15: ST-18286) carried the American conjugative plasmid (pConj)
207 containing *tet*(*M*) (NEIS2210) allele 2 [25]. This allele shares 100% sequence similarity with
208 Ng *tet(M*) alleles consistent with HGT [26]. A markerless pConj, lacking *tet*(*M*), was present in
209 one isolate (ID: 150947, cnl: P7-2, 13-7: F5-148: ST-18281).

210 A total of 14 isolates (n = 14/35, 40%) possessed a chromosomally-encoded *tet*(*B*)
211 locus, inserted between the catalase gene, *catA* (NEIS0211) and an RNA polymerase sigma
212 factor (NEIS0212) (Figure 4). The locus consists of a *tet*(*B*) gene (NEIS2907) which functions
213 as a tetracycline efflux pump and its repressor gene, *tetR*(*B*) (NEIS2927) [27]. All 14 isolates
214 possessed the same *tet*(*B*) allele which demonstrated 100% sequence similarity with a *tet*(*B*)
215 gene from *Haemophilus influenzae* (GenBank accession number CP131723). It also shared
216 99.92% identity with the complete nucleotide sequence of transposon Tn*10* (GenBank
217 accession number AF162223). All *tet*(*B*)-positive isolates carried the tetracycline repressor
218 gene *tetR*(*B*) (NEIS2927). Eleven of these isolates possessed functional *tetR*(*B*) genes with
219 the remaining four *tetR*(*B*) sequences (allele 8) containing a premature stop codon resulting
220 in an inactive repressor, consistent with constitutive expression of *tet*(*B*). Nine of the 14 *tetB*
221 positive isolates were MenB (9/14, 64.28%), several belonging to the same lineages
222 (Supplementary Figure 2B).

223 We found a significant association between the presence of *tet*(*M*) and MSMCARR
224 isolates. Of the 45,317 publicly available Nm whole genome records deposited in PubMLST,
225 only 15 possessed a *tet*(*M*) pConj plasmid (MSMCARR: n = 1/35, PubMLST: n = 15/45,317;
226 OR = 83.60, 95% CI: 1.94–579.26, $p = 0.013$). The same significant association was detected
227 for *tet*(*B*) where of the 45,317 Nm WGS records, only 669 contained the *tet*(*B*) locus
228 (MSMCARR: n = 14/35, PubMLST: n = 669/45,317; OR = 45.48, 95% CI: 21.84 - 92.47, $p <$
229 2.2×10^{-16}).

230

231

232 Concurrent AMR phenotypes

233 Tetracycline resistance (TetR) was the most frequent phenotype (n = 15), followed by reduced
234 susceptibility to penicillin (PenR, n = 10), and ciprofloxacin (CipR, n = 9) (Figure 5). Nm with
235 reduced susceptibility to azithromycin (AziReduced) was present in several isolates (n = 14).
236 Co-resistance between tetracycline and penicillin (n = 2) or ciprofloxacin (n = 7) was observed,
237 with only one isolate exhibiting triple-resistance combinations. No isolate exhibited concurrent
238 resistance to all four agents tested. Overall, these data highlight the predominance of
239 tetracycline resistance and the emergence of discrete clusters of dual or multidrug resistant
240 meningococci that are circulating in the meningococcal population prior to doxyPEP and
241 4CMenB vaccination rollout.

242

243 **Discussion**

244 *N. gonorrhoeae* (Ng) has developed extensive antimicrobial resistance (AMR), with both the
245 number of cases and the proportion exhibiting resistance rising globally. In response, the UK
246 has introduced preventative measures against gonococcal infections, including the *N.*
247 *meningitidis* (Nm) vaccine 4CMenB [18, 28]. Although interventions such as doxyPEP and the
248 4CMenB vaccine aim to reduce bacterial sexually transmitted infections (STIs), their
249 ecological impact on bystander *Neisseria* species remains poorly understood. In this study,
250 meningococcal carriage was investigated in MSM before the implementation of 4CMenB and
251 doxyPEP to establish a baseline for understanding how these measures may alter Nm
252 carriage, antimicrobial resistance, and population structure.

253 Consistent with previous studies, we found a high Nm carriage rate (21.26%) in MSM,
254 approximately fivefold greater than that reported in UK adolescents [8, 9, 29]. This elevated
255 prevalence likely reflects behaviours promoting close physical contact and increased
256 opportunities for oral-urogenital transmission. Over 90% of carriers reported recent oral or
257 anal sexual contact, suggesting that Nm, like Ng, is transmitted within sexual networks and
258 may colonise multiple anatomical sites. The significant association between Nm carriage and
259 throat, urethral, or rectal gonorrhoea observed here supports frequent co-colonisation and
260 shared transmission pathways between the two species.

261 In settings where oropharyngeal gonorrhoea and antibiotic use are common, co-
262 carriage of *Neisseria* species facilitates interspecies recombination, accelerating the
263 dissemination and selection of antimicrobial resistance determinants [30, 31]. The detection
264 of Nm isolates with reduced susceptibility to penicillin (94%), ciprofloxacin (25%), tetracycline
265 (42%), and azithromycin (37%) provides compelling evidence of this with the presence of both
266 plasmid and chromosomally-mediated tetracycline resistance (*tet*(*M*) and *tet*(*B*) respectively)
267 suggesting multiple routes of AMR acquisition. The *tet*(*B*) locus shared near-identical
268 sequence identity with *H. influenzae*, indicating horizontal gene transfer (HGT) across
269 respiratory bacterial species. Such interspecies exchange likely occurs within the oropharynx,

270 a densely colonised anatomical niche [32] where repeated antibiotic exposure, including
271 doxycycline for STI treatment or prophylaxis, is likely to exert selection pressure.

272 The rarity of *tet*(*M*) and *tet*(*B*) in global Nm genome collections (0.03% and 1.5%,
273 respectively, among >45,000 isolates) highlights the significance of this finding here. This
274 disproportionate frequency indicates that antibiotic use within sexual networks may already
275 be selecting for resistant Nm lineages prior to widespread doxyPEP implementation, possibly
276 as a result of individuals self-sourcing antibiotics for STI prophylaxis [33]. The co-occurrence
277 of multiple resistance mechanisms suggests that multidrug-resistant Nm populations are
278 emerging through both horizontal acquisition and local expansion. Future genomic analyses
279 comparing mobile elements and resistance gene synteny between Ng, Nm, and commensal
280 *Neisseria* could clarify the mechanisms underlying AMR gene flow.

281 The lower Nm carriage rates reported in adolescents compared to MSM may reflect
282 differences in vaccine exposure. Introduction of the MenACWY conjugate vaccine in 2015
283 reduced MenW and MenC carriage through herd immunity [34, 35]. However, MSM are not
284 routinely offered MenACWY, and our data show that the South American–UK MenW:CC11
285 sublineage is circulating in this group. The clinical significance of this finding is underscored
286 by the atypical presentations and high fatality rates associated with MenW:CC11 invasive
287 meningococcal disease, highlighting the importance of continued vaccine awareness in sexual
288 health settings [36].

289 Although the 4CMenB vaccine has reduced MenB IMD in the general population, its
290 effect on Nm carriage is limited, likely due to antigenic diversity among circulating strains [37,
291 38]. The predominance of MenB isolates belonging to CC4821 and ST-5662 lineages, both
292 harbouring *tet*(*B*) and exhibiting unknown predicted cross-reactivity with 4CMenB, suggests
293 that these lineages may persist despite vaccination. These findings identify a genetically and
294 epidemiologically distinct group of meningococci associated with sexual transmission,
295 highlighting the need to monitor whether vaccine-driven selection pressures alter the
296 distribution of such lineages in MSM populations.

297 These results have broader public health implications. MSM experience
298 disproportionately high antibiotic exposure due to recurrent STI treatment and emerging use
299 of doxyPEP, creating an environment for AMR emergence across multiple commensal species
300 [39]. Surveillance strategies should therefore include oropharyngeal *Neisseria* isolates from
301 MSM, as resistance trends in this anatomical niche may precede those detected in Ng
302 surveillance [40]. Incorporating genomic AMR monitoring into UKHSA (UK Health Security
303 Agency) sexual health frameworks could enable early identification of resistant meningococci
304 or recombinant *Neisseria* species with clinical relevance.

305 There are several limitations in this study. This was a single-centre, cross-sectional
306 study with a small sample size and no longitudinal follow-up. Antibiotic exposure history was
307 limited to the preceding two weeks, which may underestimate selection pressure.
308 Furthermore, while the study excluded individuals recently treated with antibiotics, undetected
309 subclinical exposures (e.g., post-treatment prophylaxis or unrecorded PrEP-associated
310 antibiotics) may have influenced findings. Larger, multi-site, and longitudinal studies will be
311 required to evaluate whether resistant Nm lineages expand following doxyPEP and 4CMenB
312 implementation to determine how these interventions shape the oropharyngeal microbiome.

313 From an evolutionary perspective, the convergence of antibiotic pressure, high
314 transmission connectivity, and multispecies colonisation creates an environment for genetic
315 reassortment within *Neisseria* populations. MSM sexual networks thus represent important
316 micro-ecosystems where AMR determinants may emerge and subsequently disseminate
317 beyond the community through social and clinical contact. Understanding these processes is
318 essential not only for STI control but also for anticipating resistance evolution in other
319 *Neisseria* species.

320 In summary, this study identifies a high prevalence of Nm carriage and multidrug
321 resistance in MSM prior to doxyPEP and 4CMenB rollout, including unprecedented rates of
322 tetracycline and azithromycin resistance. These findings provide early evidence that sexual
323 networks constitute a distinct environment for *Neisseria* evolution and AMR selection. As STI

prevention strategies expand, integrated genomic and epidemiological surveillance will be critical to detect emerging resistant lineages, evaluate the impact of combined prophylactic interventions, and guide antimicrobial stewardship and vaccination policies in this high-risk population.

329 # Methods

330 Participant recruitment and Isolate Collection

331 Adult (≥18 years) MSM attending the Mortimer Market Centre Sexual Health Clinic in London,
332 United Kingdom between May to September 2023 were invited to take part in the study. MSM
333 were defined as individuals who identified as men, including those assigned male at birth and
334 transgender men. Charcoal-amies oropharyngeal swabs were collected regardless of
335 gonorrhoea diagnosis and stored at 4℃ until plating. Participants who took antibiotics within
336 two weeks prior to sampling were excluded. At the time of sampling, all participants completed
337 a lifestyle questionnaire interrogating basic demographics, sexual behaviours, and clinical
338 information with data stored on the REDCap database [41].

339 The study complies with relevant ethical regulations and was approved by the Health
340 Research Authority and Research Ethics Committee (REC reference: 23/PR/0019). Written
341 informed consent was obtained from participants. Participant's samples and data were
342 pseudonymised using a unique numerical identification number.

343 Nucleic Acid Amplification tests (NAATs) were conducted on self-collected Aptima®
344 multitest swabs (Hologic Inc, Massachusetts, USA) using the Aptima® Combo 2™ assay on
345 the Hologic Panther® system (Hologic Inc, Massachusetts, USA).

346 Whole-Genome Sequencing and Isolate Characterisation

347 Within 24 hours of sampling, swabs were plated on chocolate-VCAT agar containing vitox with
348 plates (Southern Group Laboratory) incubated at 37°C in a water-saturated atmosphere for
349 12 hours in 5% CO_2. Gram-negative, oxidase-positive diplococci (GND +ve) were isolated and
350 whole-genome sequenced using the Illumina MiSeq platform (Illumina, Inc., San Diego, USA).
351 Raw sequence data were assembled using SPAdes [42] and resulting assemblies were
352 uploaded to the genomics platform, PubMLST (https://pubmlst.org/neisseria) for species
353 identification and isolate characterisation [43]. Annotations included capsule genogroup,

354 MLST sequence type (ST), clonal complex (CC), fine-typing (PorA_VR1, PorA_VR2, and
355 FetA_VR), and AMR loci including NEIS0414 (*ponA*), NEIS1753 (*penA*), NEIS1320 (*gyrA*),
356 NEIS1525 (*parC*), NEIS2210 (*tet*(*M*)), NEIS2907 (*tet*(*B*)), and NEIS2927 (*tetR*(*B*)) (Table 5).

357 WGS data from 20,123 publicly available MenB isolates deposited in PubMLST were
358 compared with MenB isolates from this study using the core-genome (cg) MLST scheme,
359 cgMLST v3 [44]. A minimum spanning tree was generated and annotated by CC and *tet*(*B*)
360 distribution.

361 Predicted Vaccine Coverage

362 Prevention of IMD is possible either through immunisation using conjugate protein-
363 polysaccharide vaccines targeting Nm expressing capsular serogroups A, C, W, and Y (e.g.
364 MenACWY) or through the use of protein-based Nm vaccines including, 4CMenB (Bexsero;
365 GSK) and rLP2086 (Trumenba; Pfizer, Inc), licensed for the prevention of MenB IMD. The
366 protein antigens contained in these vaccines are different and display significant protein
367 sequence diversity [45]. Both vaccines contain factor H binding protein (fHbp): one
368 recombinant peptide variant in Bexsero (peptide 1) and 2 native lipidated peptide variants in
369 Trumenba (peptides 45 and 55). Bexsero also contains the recombinant proteins neisserial
370 heparin-binding antigen (NHBA [peptide 2]) and *Neisseria* adhesin A (NadA [peptide 8])
371 combined with the PorA-containing (variable region 2 [VR2]); peptide 4) outer-membrane
372 vesicle from the MeNZB vaccine [22]. The diversity of 4CMenB vaccine antigens can be
373 characterised from WGS using the Bexsero antigen sequence typing (BAST) scheme resulting
374 in BAST sequence types which can be used to assess diversity and similarity to antigen
375 variants included in vaccine formulations. The Deduced Vaccine Antigen Reactivity
376 (MenDeVAR) Index [22] has in addition been developed to provide evidence-based
377 information on the presence and possible immunological cross-reactivity of the different
378 meningococcal vaccine antigen variants present in 4CMenB and rLP2086 and is publicly
379 available on PubMLST. As the protein antigens in these vaccines are not MenB specific, all

380 isolates were tested regardless of serogroup. The Bexsero® Antigen Sequence Typing scheme
381 [23] compares genomes with the Bexsero vaccine antigen variants: fHbp peptide 1, NHBA
382 peptide 2, NadA peptide 8, and PorA VR2 4. The Trumenba® reactivity analyses the fHbp
383 peptide locus (peptides 45 and 55).

384 Genotypic and phenotypic antimicrobial resistance

385 Loci defined in pubmlst.org/neisseria are allocated a value free nomenclature using the prefix
386 NEIS followed by 4 digits. This includes a total of 10 loci commonly associated with AMR in
387 Nm and Ng (Table 5). ResFinder v7.4.2 was used to screen for additional AMR genes that
388 may not be defined in PubMLST, using the Basic Local Alignment Search Tool (BLAST)
389 (http://blast.ncbi.nlm.nih.gov/Blast.cgi), searching for sequences with 80%-100% similarity
390 [46]. Sequences identified using ResFinder were then queried against the database in
391 PubMLST.org/neisseria to retrieve NEIS identifiers. Alleles designated by PubMLST for each
392 isolate were downloaded as FASTA files and imported into MEGA11 [47] where deduced
393 amino acid sequences were aligned using MUSCLE [48] and amino acid substitutions
394 associated with AMR and internal stop codons were identified.

395 The *tet*(*B*) locus was confirmed by identifying: (i) an exact match to the NMB0217 open reading
396 frame (ORF) (GenBank accession AE002379) from the Nm isolate, MC58, located 30 base
397 pairs downstream of *tet*(*B*); (ii) a downstream ORF with 98% similarity to CP000381 from strain
398 053442 (GenBank accession CP000381.1) adjacent to *tetR*(*B*); and (iii) homology with Tn10
399 transposon. The *tet*(*B*) locus is flanked by the catalase gene, *catA* (NEIS0211) and an RNA
400 polymerase sigma factor (NEIS0212). This region was extracted from the reference Nm strain
401 MC58, two *tet*(*B*) positive Nm isolates from this study (Ids: 150947 and 150923) and the locus
402 described by Takahashi *et al* [27]. Sequence data were then compared using the Artemis
403 Comparison Tool [49].

404 Minimum inhibitory concentrations (MICs) for azithromycin, ciprofloxacin, benzylpenicillin, and
405 tetracycline were determined using E-Tests (bioMerieux) and interpreted according to

406 European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints v15.0
407 [50]. Antimicrobial susceptibility testing was performed on Mueller Hinton agar plates
408 supplemented with 5% defibrinated sheep blood (Thermo Scientific Oxoid) and incubated at
409 37°C in 5% CO_2.

410 Penicillin susceptibility was inferred as follows: isolates with penicillin MICs ≤0.06 mg/L were
411 categorised as 'susceptible, standard exposure (S)' (where there is a high likelihood of
412 therapeutic success using a standard dosing regimen of the agent) and isolates with penicillin
413 MICs >0.25 mg/L were categorised as 'resistant (R)' (where there is a high likelihood of
414 therapeutic failure even when there is increased exposure). Isolates with intermediate
415 penicillin MICs were categorised as 'susceptible, increased exposure (I)' (where there is a high
416 likelihood of therapeutic success because exposure to the agent is increased by adjusting the
417 dosing regimen or by its concentration at the site of infection) [51]. Azithromycin breakpoints
418 have not been established for Nm and therefore, four MIC categories were applied here based
419 on azithromycin resistance described in Ng: susceptible (≤0.25 mg/L), intermediate (>0.25–
420 0.5), low-level resistance (1–2), and medium-level resistance (4–32) [52].

421 The Upset plot was generated using a custom python script. Minimum inhibitory concentration
422 (MIC) data for penicillin, ciprofloxacin, tetracycline, and azithromycin were converted into
423 binary resistance variables based on EUCAST v15.0 clinical breakpoints.
424 Values equal to or exceeding the resistance threshold were coded as *True* (resistant or
425 reduced susceptibility), and all others as *False*. These datasets were then used to visualise
426 resistance overlap patterns using an UpSet plot, generated in Python (v3.9) with the pandas,
427 `matplotlib`, and `upsetplot` packages [53]. The `from_indicators` function was applied
428 to aggregate intersection counts across all possible phenotype combinations, and the UpSet
429 class was used to plot intersection sizes and shared resistance categories. All intersections
430 with at least one isolate were displayed `(min_subset_size = 0)`, ensuring complete
431 representation of resistance overlaps.

432 <u>Causal Inference Model and Statistical Analyses</u>

Lifestyle questionnaire responses were used to construct a directed acyclic graph (DAG) in R version 4.3.2 (R Core Team, 2023) using `dagitty` [54], `ggdag` [55], `ggplot2` [56], and `DiagrammeR` [57]. The outcome variable was Nm oropharyngeal carriage (Supplementary Figure 1). Causal exposures were modelled as the following: HIV status, Perform anilingus, Condomless anal sex, Male partner frequency, Perform fellatio, Kissing frequency, Smoker, Vape, and Waterpipe. Non-causal exposures included Taken PrEP, Fisting someone, Getting fisted, Sex toys and Mutual masturbation. These variables and age were treated as confounders for other exposures. Multivariate logistic regression models for each exposure, including adjusted odd ratios (aOR), 95% confidence intervals (CI), and *p-values* were built based on the DAG. Confounders that were strongly correlated with the exposure were excluded from the model to avoid collinearity and overfitting. For example, in the exposure of 'Kissing frequency', the confounder 'Male partners frequency' was excluded as the behaviours were highly overlapping

Statistical tests were executed in R version 4.3.2 (R Core Team, 2023) using `dyplr`, `epitools`, `readxl`, and `tidyverse` packages [56]. Univariate logistic regression models were performed to analyse associations between clinical variables and carriage, and to obtain unadjusted odds ratios (OR). To prevent model overfit, categories with very low frequencies were combined with similar categories or excluded. The model was not run for demographic characteristics due to very low frequencies and high levels in each category. $\chi 2$ tests or Fisher's exact tests were calculated where appropriate. ORs could not be calculated for factors with zero responses in categories. Fisher's exact tests were conducted to assess whether the presence of *tet*(*M*) (MSMCARR: n = 1/37, PubMLST: n = 15/45,317) and *tet*(*B*) (MSMCARR: n = 15/37, PubMLST: n = 669/45,317), were more frequently associated with the Nm study isolates than with Nm WGS in PubMLST. Statistical significance was defined as *p*-values below 0.05 and recorded to three or more decimal places to prevent misinterpretation from premature rounding.

460 **Data availability**

461 Whole genome sequence data generated in this study are available on the PubMLST
462 database (https://pubmlst.org/neisseria).

463 **Author contributions**

464 A.M. contributed data analyses, interpretation, and manuscript writing; W.L. provided
465 statistical analyses; M.K. contributed study design, participant recruitment, consent and
466 sampling, data analyses and manuscript editing; E.S. contributed study design, project
467 management; Y.G. contributed participant recruitment, consent, sampling and manuscript
468 editing; C.K. contributed participant recruitment, consent, sampling and manuscript editing;
469 F.N. contributed participant recruitment, consent, sampling and manuscript editing; R.G.
470 contributed manuscript editing and data interpretation; O.B.H contributed microbiology and
471 molecular microbiology analyses, data analyses and interpretation, manuscript writing and
472 editing.

473

474 ## Tables

475 **Table 1 Participant demographics**

Variable	Carriers (n = 37)	Non-carriers (n = 137)	Total Count (n = 174)	*p*-value
Age				
18 to 24	3 (8.11%)	8 (5.84%)	11 (6.32%)	
25 to 34	12 (32.43%)	34 (24.82%)	46 (26.44%)	
35 to 44	8 (21.62%)	47 (34.31%)	55 (31.61%)	
45 to 54	9 (24.32%)	29 (21.17%)	38 (21.84%)	
55 to 64	5 (13.51%)	14 (10.22%)	19 (10.92%)	
65 to 74	0 (0%)	5 (3.65%)	5 (2.87%)	0.544
Ethnicity				
Any other Asian Background	0 (0%)	8 (5.84%)	8 (4.60%)	
Any other Black Background	0 (0%)	2 (1.46%)	2 (1.15%)	
Any other white Background	11 (29.73%)	37 (27.01%)	48 (27.59%)	
Asian or Asian British: Chinese	1 (2.70%)	8 (5.84%)	9 (5.17%)	
Asian or Asian British: Indian	1 (2.70%)	2 (1.46%)	3 (1.72%)	
Asian or Asian British: Pakistani	0 (0%)	3 (2.19%)	3 (1.72%)	
Black or black British: African	1 (2.70%)	2 (1.46%)	3 (1.72%)	
Black or black British: Caribbean	2 (5.41%)	5 (3.65%)	7 (4.02%)	
Latino	0 (0%)	7 (5.11%)	7 (4.02%)	
Mixed: White and Asian	1 (2.70%)	1 (0.73%)	2 (1.15%)	
Mixed: White and Black African	0 (0%)	2 (1.46%)	2 (1.15%)	
Mixed: White and Black Caribbean	1 (2.70%)	3 (2.19%)	4 (2.30%)	
White British	12 (32.43%)	49 (35.77%)	61 (35.06%)	
White Irish	2 (5.41%)	4 (2.92%)	6 (3.45%)	
Other	5 (13.51%)	4 (2.92%)	9 (5.17%)	0.278
Sexual Orientation				
Bisexual	1 (2.70%)	10 (7.30%)	11 (6.32%)	
Heterosexual	0 (0%)	1 (0.73%)	1 (0.57%)	
Homosexual	35 (94.59%)	122 (89.05%)	157 (90.23%)	
Pansexual	1 (2.70%)	2 (1.46%)	3 (1.72%)	
No label	0 (0%)	2 (1.46%)	2 (1.15%)	0.722
Housemates				
0	14 (37.84%)	36 (26.28%)	50 (28.74%)	
1	17 (45.95%)	69 (50.36%)	86 (49.43%)	
2	1 (2.70%)	17 (12.41%)	18 (10.34%)	
3	3 (8.11%)	7 (5.11%)	10 (5.75%)	
4	2 (5.41%)	4 (2.92%)	6 (3.45%)	
≥5	0 (0%)	4 (2.92%)	4 (2.30%)	0.256

476

477

478 **Table 2. Univariate Analysis of Clinical Characteristics (n = 37).**

Variable	OR	(95% CI)	*p*-value
Throat gonorrhoea NAAT*			
Negative	1 (ref)		
Positive	2.96	(1.00-8.37)	0.049
Rectal gonorrhoea NAAT			
Negative	1 (ref)		
Positive	1.70	(0.56-4.62)	0.328
Urethral gonorrhoea NAAT*			
Negative	1 (ref)		
Positive	5.11	(1.45-18.78)	0.012
Throat chlamydia NAAT			
Negative	1 (ref)		
Positive	1.89	(0.16-13.83)	0.609
Rectal chlamydia NAAT			
Negative	1 (ref)		
Positive	0.45	(0.01-3.54)	0.686
Urethral chlamydia NAAT			
Negative	1 (ref)		
Positive	1.50	(0.14-9.68)	0.641
Cold/sore throat			
No	1 (ref)		
Yes	0.52	(0.01-4.25)	1.000
Syphilis			
No	NA	NA	
Yes	NA	NA	0.348

479

480 OR, odds ratio; CI, confidence interval; ref, reference; NA, not applicable due to zero
481 responses in one or more categories; NAAT, nucleic acid amplification test; *included in
482 multivariate analysis as obtained a relaxed *p*-value (<0.25).

483

Table 3. *N. meningitidis* isolate characterisation

PubMLST ID	Strain designation	BAST ST	fHbp allele (variant)	NHBA peptide variant	NadA peptide variant	MenDeVAR Bexsero®	MenDeVAR Trumenba®
150935	C: P5-1, 10-8: F3-6: ST-11 (cc11)	4962	896 (1)	1168	2	-ve [c]	- ve [c]
150939	W: P5, 2: F1-1: ST-11 (cc11)	2	22 (2)	29	6	+ve [b]	-ve [c]
150949	W: P5, 2: F1-1: ST-11 (cc11)	2	22 (2)	29	6	+ve [b]	- ve [c]
150954	W: P5, 2: F1-1: ST-11 (cc11)	2	22 (2)	29	6	+ve [b]	- ve [c]
150958	W: P5, 2: F1-1: ST-11 (cc11)	2	22 (2)	29	6	+ve [b]	- ve [c]
150923	B: P17-6, 23: F3-36: ST-11311 (cc4821)	N/A	16 (2)	1965	0	-ve [c]	+ve [b]
150964	B: P17-6, 23: F3-36: ST-3469 (cc4821)	811	16 (2)	669	0	-ve [c]	+ve [b]
150967	B: P20, 23: F1-5: ST-12480 (cc4821)	4970	16 (2)	1210	0	-ve [c]	+ve [b]
150930	B: P21-2, 23: F3-43: ST-5662	4901	18 (2)	1511	0	-ve [c]	- ve [c]
150933	B: P21-2, 23-1: F3-43: ST-5662	4668	18 (2)	1511	0	-ve [c]	- ve [c]
150937	B: P21-2, 23-1: F3-43: ST-5662	4668	18 (2)	1511	0	-ve [c]	- ve [c]
150951	B: P21-2, 23-7: F3-43: ST-5662	4685	18 (2)	1511	0	-ve [c]	- ve [c]
150968	B: P21-2, 23-7: F3-43: ST-5662	4685	18 (2)	1511	0	-ve [c]	- ve [c]
150924	B: P21-2, 23-3: F3-8: ST-11563	4903	18 (2)	1524	0	-ve [c]	- ve [c]
150965	B: P21-2, 28: F5-64: ST-17921	N/A	21 (2)	1966	0	-ve [c]	+ve [b]
150945	B: P21-2, 23-1: F3-43: ST-17927	4668	18 (2)	1511	0	-ve [c]	- ve [c]
150963	B: P7, TD: F5-81: ST-18285	N/A	16 (2)	816	0	-ve [c]	+ve [b]
150953	X: P7-2, 13-43: F5-7: ST-18282	4709	19 (2)	513	0	-ve [c]	+ve [b]
150943	Z: P12-6, 13-75: F5-7: ST-5953	N/A	22 (2)	912	0	-ve [c]	- ve [c]
150944	Z: P18-47, 14-13: F5-7: ST-5953	4963	22 (2)	601	0	-ve [c]	- ve [c]
150929	Z: P18-1, 30: F5-7: ST-18280	N/A	22 (2)	601	0	-ve [c]	- ve [c]
150955	Z: P22-46, 10-1: F5-7: ST-18283	4965	16 (2)	601	0	-ve [c]	+ve [b]
150956	Z: P21, 16: F5-17: ST-18284	4966	19 (2)	1501	0	-ve [c]	+ve [b]

150969	Z: P22, 14-6: F3-15: ST-18286	N/A	101 (2)	237	0	-ve [c]	- ve [c]
150948	cnl: P12-1, 23: F1-12: ST-2153 (cc162)	4697	21 (2)	20	0	-ve [c]	+ve [b]
150934	cnl: P5-1, 10-62: F5-5: ST-823 (cc198)	4961	4 (1)	10	0	+ve [b]	+ve [b]
150957	cnl: P18-4, 3: F1-22: ST-1136 (cc1136)	4967	94 (3)	145	0	-ve [c]	- ve [c]
150961	cnl: P17-1, 23-1: F1-5: ST-1768	4968	119 (2)	53	0	-ve [c]	- ve [c]
150926	cnl: P18-1, 3: F5-5: ST-11312	N/A	544 (1)	0	TD	-ve [c]	- ve [c]
150932	cnl: P18-1, 3: F5-5: ST-11312	N/A	544 (1)	749	TD	-ve [c]	- ve [c]
150931	cnl: P21-2, 23: F3-8: ST-11563	4424	18 (2)	1524	0	-ve [c]	- ve [c]
150966	cnl: P21-2, 13-1: F5-1: ST-11563	4969	18 (2)	1511	0	-ve [c]	- ve [c]
150927	cnl: P22, 14: F5-148: ST-12128	4926	30 (3)	819	0	-ve [c]	+ve [b]
150942	cnl: P21-2, 23-3: F3-8: ST-18215	4723	18 (2)	1511	0	-ve [c]	- ve [c]
150947	cnl: P7-2, 13-7: F5-148: ST-18281	4964	106 (2)	819	0	-ve [c]	- ve [c]

N/A: not available, allele at the end of a contig; -ve: unreactive; +ve: cross-reactive; [a]: isolate contains exact vaccine antigen variants; [b]: isolate contains ≥1 cross-reactive vaccine antigen variants; [c]: isolate contains an antigen for which there is insufficient data or has yet to be tested in experimental studies.

Table 4. Isolate AMR genotypic and phenotypic results

PubMLST ID, capsule group, ST or CC	PEN MIC (µg/ml)	*penA* allele	CIP MIC (µg/ml)	*gyrA* allele	TET MIC (µg/ml)	*tet(B)*; *tet(R)*; *tet(M)* alleles	AZI MIC (µg/ml)	*mtrD* *mtrR* *mtrR*_promoter alleles
150935 NG: cc11	0.125 (I)	316[a]	0.006 (S)	4	0.5 (S)	0	0.125 (S)	24; 41; 15
150939 W: cc11	0.5 (R)	9[a]	0.006 (S)	4	1 (S)	0	1 (S)	4108[e]; [S]; 16
150949 W: cc11	0.25 (I)	9[a]	0.004 (S)	4	0.5 (S)	0	0.125 (S)	4108[e]; 1246[h]; 16
150954 W: cc11	0.25 (I)	9[a]	0.004 (S)	4	0.5 (S)	0	0.5 (S)	4108[e]; [S]; 16
150958 W: cc11	0.38 (R)	9[a]	0.008 (S)	4	1 (S)	0	1 (S)	4108[e]; [S]; 16
150923 B: cc4821	0.25 (I)	9[a]	0.004 (S)	12	8 (R)	1; 1; 0	0.23 (S)	407; 1216; 5
150964 B: cc4821	0.25 (I)	9[a]	0.004 (S)	12	12 (R)	1; 1; 0	0.125 (S)	407; 2411; 5
150967 B: cc4821	0.19 (S)	9[a]	0.004 (S)	12	0.5 (S)	0	0.125 (S)	24; 44; 5
150933 B: ST-5662	0.125 (I)	7[a]	0.125 (R)	146[b]	16 (R)	1; 8; 0	0.25 (S)	1781; 2409; 57
150930 B: ST-5662	0.125 (I)	7[a]	0.125 (R)	146[b]	0.75 (S)	0	0.094 (S)	1781; 7; 5
150937 B: ST-5662	0.19 (I)	7[a]	0.125 (R)	146[b]	4 (R)	1; 8; 0	0.125 (S)	1781; 7; 5
150951 B: ST-5662	0.125 (I)	7[a]	0.125 (R)	146[b]	16 (R)	1; 8; 0	0.125 (S)	1781; 7; 5
150968 B: ST-5662	0.047 (S)	1	0.125 (R)	146[b]	12 (R)	1; 1; 0	0.19 (S)	1781; 7; 5
150924 B: ST-11563	0.125 (I)	914[a]	0.125 (R)	361[b]	8 (R)	1; 1; 0	0.125 (S)	1781; 9; 5
150945 B: ST-17927	0.19 (I)	7[a]	0.125 (R)	146[b]	12 (R)	1; 8; 0	0.047 (S)	1781; 7; 5
150963 B: ST-18285	0.38 (R)	380[a]	0.004 (S)	3	0.5 (S)	0	1.5 (R)	5613[f]; 3139[$]; 11
150965 B: ST-17921	0.032 (S)	4	0.004 (S)	12	48 (R)	1; 1; 0	0.094 (S)	2417; 10; 7
150953 X: ST-18282	0.25 (I)	5	0.004 (S)	12	0.5 (S)	0	0.064 (S)	2003;1111[h]; 60
150929 Z: ST-18280	0.125 (I)	66[a]	0.003 (S)	11	0.38 (S)	0	0.94 (S)	1482[e]; 574; 19
150943 Z: ST-5953	0.19 (I)	66[a]	0.003 (S)	11	12 (R)	1; 4; 0	0.5 (S)	5593[e]; 2833[h]; 58
150944 Z: ST-5953	0.38 (R)	66[a]	0.004 (S)	11	0.5 (S)	0	0.38 (S)	5608[e]; 143[j]; 59
150955 Z: ST-18283	0.094 (I)	1257[a]	0.008 (S)	4	0.38 (S)	0	0.38 (S)	5196; 2041[i]; 61
150956 Z: ST-18284	0.19 (I)	14[a]	0.004 (S)	11	0.75 (S)	0	1.5 (R)	5611[g]; 2410; 48
150969 Z: ST-18286	0.094 (I)	127[a]	0.004 (S)	2	4 (R)	0; 0; 2	16 (R)	69[d]; 7; 62

150948 cnl: cc162	0.19 (S)	9[a]	0.006 (S)	4	0.75 (S)	0	0.38 (S)	5610[g]; 31; 5
150934 cnl: cc198	0.125 (I)	9[a]	0.004 (S)	3	0.5 (S)	0	0.094 (S)	65; 8; 5
150957 cnl: cc1136	0.19 (I)	7[a]	0.004 (S)	2	0.75 (S)	0		5612[e]; 973[h]; 56
150961 cnl: ST-1768	0.25 (I)	9[a]	0.003 (S)	3	0.25 (S)	0	0.064 (S)	102; 7; 5
150926 cnl: ST11312	0.38 (R)	66[a]	0.003 (S)	4	0.5 (S)	0	1.5 (R)	5607[e]; 2408[h]; 56
150932 cnl: ST11312	0.125 (I)	66[a]	0.004 (S)	4	0.25 (S)	0	0.125 (S)	65; 11; 5
150931 cnl: ST11563	0.125 (I)	914[a]	0.125 (R)	361[b]	12 (R)	1; 1; 0	0.125 (S)	5767[g]; 633[h]; 18
150966 cnl: ST11563	0.094 (I)	914[a]	0.5 (R)	361[b, c]	16 (R)	1; 1; 0	0.064 (S)	1781; 7; 5
150927 cnl: ST12128	0.094 (I)	203[a]	0.002 (S)	12	0.19 (S)	0	0.125 (S)	104[d]; 1; 5
150942 cnl: ST18215	0.125 (I)	914[a]	0.003 (S)	840	12 (R)	1; 6; 0	0.094 (S)	1781; 7; 5
150947 cnl: ST18281	0.094 (I)	203[a]	0.002 (S)	12	12 (R)	1; 4; 0		2781; 416; 5

S: susceptible; I: intermediate; R: resistant;

[S]: NEIS1635 (*mtrR*) allele lacks stop codon; $: *mtrR* allele has a premature stop codon;

[a]: *penA* allele contains amino acid substitutions: F504L; A510V; I515V; H541N; I566V;

[b]: gyrA allele contains amino acid substitution: T91I; [c]: isolate contains *parC* allele with S87R amino acid substitution

mtrD allele contains: [d]: F854L; [e]: K823E; F854L; [f]: R714G; S821A; K823E; F854L; [g]: S821A; K823E; F854L

mtrR allele contains: [h]: D79N; A86T; S183N; [i]: A39T; D79N; [j]: H105Y; S183N; all *mtrR* promoter sequences have the A12C nucleotide substitution

Table 5. AMR Determinants analysed

Locus	Amino acid substitutions known to confer resistance (published MIC values are indicated where available)	References
Beta-lactams		
NEIS0414 (*ponA*)	L421P	[58]
NEIS1753 (*penA)* &	Penicillin: F504L, A510V, I515V, H541N, I566V	[59]
'*penA*	Third-generation cephalosporins: A311V, I312M, V316T, T483S, G545S	[60]
Fluoroquinolones		
NEIS1320 (*gyrA)*	T91I/F; D95G/A/N/Y; T173A	[61, 62]
NEIS1525 (*parC*)	D86N, S87R, S88P, E91G	
Tetracyclines		
NEIS2210 *(tet(M))*	Plasmid-encoded *tet*(*M*)	
NEIS2907 *(tet(B))*		[27, 63]
NEIS2927 *(tetR(B))*		
Efflux pumps		
NEIS1633 (*mtrD*)	R714G; S821A; K823E; F854L	
NEIS1635 (*mtrR*)	A39T; D79N; A86T; H105Y; S183N;	
proNEIS1635 (*mtrR* promoter region)	A12C	

Figures

Figure 1. Forest plot depicting Behavioural adjusted odds ratios for causal exposures



95% confidence intervals and *p*-values (derived from likelihood ratio tests) between behavioural and Nm carriage are depicted. Black-outlined circles represent reference values where OR = 1, black-filled circles represent adjusted odd ratios, and horizontal black lines represent 95% confidence intervals. The adjusted odd ratios were derived from multivariate logistic regression models for each causal exposure including covaries identified from the directed acyclic graph (DAG). aOR, adjusted odds ratio; CI, confidence intervals, Ref, reference value. *CAS: Condomless anal sex.

Figure 2. Forest plot depicting Behavioural adjusted odds ratios for non-causal exposures



95% confidence intervals and *p*-values (derived from likelihood ratio tests) between behavioural and Nm carriage are depicted. Black-outlined circles represent reference values where OR = 1, black-filled circles represent adjusted odd ratios, and horizontal black lines represent 95% confidence intervals. The adjusted odd ratios were derived from multivariate logistic regression models for each non-causal exposure including covaries identified from the directed acyclic graph (DAG). aOR, adjusted odds ratio; CI, confidence intervals, Ref, reference value.

Figure 3. Forest Plot depicting adjusted odds ratios of clinical diagnoses and Nm carriage



95% confidence intervals and *p*-values (derived from likelihood ratio tests) between clinical results and *Nme* carriage are depicted. ORs could not be calculated for syphilis due to zero responses in categories. Black-outlined circles represent reference values where OR = 1, black-filled circles represent adjusted odd ratios, and horizontal black lines represent 95% confidence intervals. OR, adjusted odds ratio; CI, confidence intervals, Ref, reference value.

Figure 4. Artemis comparison of the *tet*(*B*) locus



Nucleotide Sequences were retrieved from the Takahashi *et al* study [27], accession number AB084246 and compared with the *tet*(*B*) locus from two MSM CARR isolates, 150947 and 150923. The *tet*(*B*) locus is flanked by the catalase gene, *katA* (NEIS0211) and an RNA polymerase sigma factor (NEIS0212). This region was extracted from the serogroup B reference genome, MC58 (accession number AE002098), which does not harbour TetB [64]. Comparisons were undertaken using the Artemis comparison tool (ACT) with the colour of the bands proportional to the percentage of sequence identity with the grey colour indicating 90 to 100% sequence identity.

Figure 5. Upset plot of concurrent resistant phenotypes



Each bar represents the number of isolates sharing specific combinations of resistance phenotypes to penicillin (PenR), ciprofloxacin (CipR), tetracycline (TetR), and azithromycin (AziReduced). Four MIC categories indicative of reduced susceptibility to azithromycin were included when generating the Upset plot: intermediate (>0.25–0.5mg/mL), low-level resistance (1–2mg/mL) and medium-level resistance (4–32mg/mL). The TetR category included isolates with MICs in the 4-48 mg/mL range; CipR included isolates with MICs 0.125-0.5 mg/mL and PenR 0.094-0.5 mg/mL. Tetracycline resistance predominated (n = 15), with co-resistance found with penicillin (n = 2) or ciprofloxacin (n = 7) but only one isolate displaying triple-resistance combinations (AziReduced+TetR+CipR). Six isolates exhibited co-resistance with azithromycin and penicillin, No isolate displayed resistance to all four agents. These data indicate that tetracycline and azithromycin resistance is widespread in this dataset, and multidrug resistance is common.

Supplementary Figure 1. Directed acyclic graph (DAG) representing the variables from the participant lifestyle questionnaire estimated to have causal effects on Nm carriage.



Supplementary Figure 2. Comparison of MenB meningococci identified in this study with all MenB WGS in PubMLST.

Panel A. Clonal complex distribution of all MenB WGS in PubMLST

Panel B. Distribution of TetB positive MenB isolates



Whole genome sequence data from 20,123 MenB were compared using the cgMLST v3 tool in PubMLST after which a minimum spanning tree was generated. Each node represents an Nm strain which is coloured by clonal complex (Panel A) or TetB presence (Panel B). Clusters of isolates sharing allelic profiles in the core genome will form groups of related isolates. MenB isolates from this study are indicated in Panel A. This shows that the majority of isolates belong to 2 main lineages, CC4821 and ST-5662. Isolates from these lineages are also predominantly TetB positive.

Bibliography

1. Christensen, H., et al., *Meningococcal carriage by age: a systematic review and meta-analysis.* The Lancet Infectious Diseases, 2010. **10**(12): p. 853-61.
2. Ladhani, S.N., et al., *Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to Neisseria meningitidis.* Lancet, 2020. **395**(10240): p. 1865-1877.
3. Caugant, D.A. and M.C.J. Maiden, *Meningococcal carriage and disease—Population biology and evolution.* Vaccine, 2009. **27**: p. B64-B70.
4. Maclennan, J., et al., *Social Behavior and Meningococcal Carriage in British Teenagers.* Emerging Infectious Diseases, 2006. **12**(6): p. 950-957.
5. Olof, S., et al., *Prevalence and persistence of Neisseria meningitidis carriage in Swedish university students.* Epidemiology and Infection, 2023. **151**: p. e25.
6. Kizil, M.C., et al., *The Prevalence, Serogroup Distribution and Risk Factors of Meningococcal Carriage in Children, Adolescents and Young Adults in Turkey Meningo-Carr-TR Study PART 3: COVID-19 Pandemic Situation.* Pediatric Infectious Disease Journal, 2025. **44**(4): p. 281-286.
7. Folaranmi, T.A., et al., *Increased Risk for Meningococcal Disease Among Men Who Have Sex With Men in the United States, 2012-2015.* Clinical Infectious Diseases, 2017. **65**(5): p. 756-763.
8. Pérez-González, A., et al., *Meningococcal carriage in men who have sex with men presenting at a sexual health unit in Spain.* Eur J Clin Microbiol Infect Dis, 2023. **42**(3): p. 287-296.
9. Doubinsky, A., et al., *Prevalence of Neisseria meningitidis carriage among men who have sex with men at a sexual health clinic in Brussels, Belgium: a cross-sectional study.* European Journal of Clinical Microbiology & Infectious Diseases, 2025. **44**(3): p. 739-745.
10. Aubert, L., et al., *Serogroup C invasive meningococcal disease among men who have sex with men and in gay-oriented social venues in the Paris region: July 2013 to December 2014.* EuroSurveillance, 2015. **20**(3).
11. Kamiya, H., et al., *Meningococcal disease among men who have sex with men - United States, January 2012-June 2015.* Morbidity Mortality Weekly Report, 2015. **64**(44): p. 1256-7.
12. Miglietta, A., et al., *Interconnected clusters of invasive meningococcal disease due to Neisseria meningitidis serogroup C ST-11 (cc11), involving bisexuals and men who have sex with men, with discos and gay-venues hotspots of transmission, Tuscany, Italy, 2015 to 2016.* EuroSurveillance, 2018. **23**(34).
13. Doyle, T.J., et al., *Concurrent Outbreaks of Hepatitis A, Invasive Meningococcal Disease, and Mpox, Florida, USA, 2021-2022.* Emerging Infectious Diseases, 2024. **30**(4): p. 633-43.
14. Jacobsson, S., et al., *Antimicrobial resistance in Neisseria gonorrhoeae and its risk groups in 23 European countries in 2022 within the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP): a retrospective observational study.* The Lancet Regional Health - Europe, 2025. **54**: p. 101318.
15. Davis, P., et al., *Gonorrhoea: rising cases and antimicrobial resistance.* BMJ, 2025. **389**: p. r1001.
16. Tzeng, Y.-L., et al., *Emergence of a new Neisseria meningitidis clonal complex 11 lineage 11.2 clade as an effective urogenital pathogen.* Proceedings of the National Academy of Sciences, 2017. **114**(16): p. 4237-4242.
17. Jansen van Rensburg, M., et al., *Detection and characterisation of Xpert CT/NG assay Neisseria gonorrhoeae diagnostic escape mutants, England, June 2025.* Eurosurveillance, 2025. **30**(36): p. 2500673.
18. UKHSA, U.H.S.A.-. *4CMenB vaccine for prevention of gonorrhoea: information for healthcare practitioners*. 2025; Available from: https://www.gov.uk/government/publications/4cmenb-vaccine-for-gonorrhoea-

information-for-healthcare-practitioners/4cmenb-vaccine-for-prevention-of-gonorrhoea-information-for-healthcare-practitioners#:~:text=4CMenB%20use%20for%20gonorrhoea&text=The%20vaccine%20is%20estimated%20to,against%20gonorrhoea%20but%20other%20STIs%20.

19. Kohli, M., et al., *Doxycycline post-exposure prophylaxis as prevention of STIs – the golden bullet?* Expert Review of Anti-infective Therapy, 2025. **23**(7): p. 445-457.
20. Retchless, A.C., et al., *Expansion of a urethritis-associated Neisseria meningitidis clade in the United States with concurrent acquisition of N. gonorrhoeae alleles.* BMC Genomics, 2018. **19**(1): p. 176.
21. Campbell, H., et al., *Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015.* EuroSurveillance, 2015. **20**(28).
22. Rodrigues, C.M.C., et al., *Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a Rapid and Accessible Tool That Exploits Genomic Data in Public Health and Clinical Microbiology Applications.* Journal of Clinical Microbiology, 2020. **59**(1): p. 10.1128/jcm.02161-20.
23. Brehony, C., et al., *Distribution of Bexsero(R) Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation.* Vaccine, 2016. **34**(39): p. 4690-4697.
24. Ohneck, E.A., et al., *A novel mechanism of high-level, broad-spectrum antibiotic resistance caused by a single base pair change in Neisseria gonorrhoeae.* mBio, 2011. **2**(5).
25. Cehovin, A., et al., *Association of Neisseria gonorrhoeae Plasmids With Distinct Lineages and The Economic Status of Their Country of Origin.* J Infect Dis, 2020. **222**(11): p. 1826-1836.
26. Yee, W.X., et al., *Evolution and exchange of plasmids in pathogenic Neisseria.* mSphere, 2023. **8**(6): p. e0044123.
27. Takahashi, H., et al., *Identification of tet(B), encoding high-level tetracycline resistance, in Neisseria meningitidis.* Antimicrobial Agents and Chemotherapy, 2002. **46**(12): p. 4045-6.
28. Saunders, J., H. Fifer, and N. Medland, *Introducing the first UK national guideline for the use of doxycycline postexposure prophylaxis (doxyPEP) for the prevention of syphilis.* Sexually Transmitted Infections, 2025. **101**(5): p. 351-352.
29. Carr JP, M.J., Plested E, Bratcher HB, Harrison OB, Aley PK, Bray JE, Camara S, Rodrigues CMC, Davis K, Bartolf A, Baxter D, Cameron JC, Cunningham R, Faust SN, Fidler K, Gowda R, Heath PT, Hughes S, Khajuria S, Orr D, Raman M, Smith A, Turner DPJ, Whittaker E, Williams CJ, Zipitis CS, Pollard AJ, Oliver J, Morales-Aza B, Lekshmi A, Clark SA, Borrow R, Christensen H, Trotter C, Finn A, Maiden MC, Snape MD, *UKMenCar4 and 'Be on the TEAM' Study Collaborators. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. .* Clinical Microbiology and Infection, 2022. **28**(12): p. 1649.e1-1649.e8.
30. Laumen, J.G.E., et al., *Antimicrobial susceptibility of commensal Neisseria in a general population and men who have sex with men in Belgium.* Scientific Reports, 2022. **12**(1).
31. Manoharan-Basil, S.S., et al., *Horizontal Gene Transfer of Fluoroquinolone Resistance-Conferring Genes From Commensal Neisseria to Neisseria gonorrhoeae: A Global Phylogenetic Analysis of 20,047 Isolates.* Frontiers in Microbiology, 2022. **13**.
32. Man, W.H., W.A. de Steenhuijsen Piters, and D. Bogaert, *The microbiota of the respiratory tract: gatekeeper to respiratory health.* Nature Reviews Microbiology, 2017. **15**(5): p. 259-270.
33. Kohli, M., et al., *Choice of antibiotics for prophylaxis of bacterial STIs among individuals currently self-sourcing.* Sexually Transmitted Infections, 2022. **98**(2): p. 158.

34. UKHSA, U.H.S.A.-. *Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2023 to 2024*. 2025 [cited 2025 12/06/2025]; Available from: https://www.gov.uk/government/publications/meningococcal-disease-laboratory-confirmed-cases-in-england-2023-to-2024/invasive-meningococcal-disease-in-england-annual-laboratory-confirmed-reports-for-epidemiological-year-2023-to-2024.
35. Lucidarme, J., et al., *Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage.* Journal of Infection, 2015. **71**(5): p. 544-552.
36. Stinson, C., et al., *Atypical presentation of invasive meningococcal disease caused by serogroup W meningococci.* Epidemiology and Infection, 2020. **148**: p. e12.
37. Marshall, H.S., et al., *Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia.* New England Journal of Medicine, 2020. **382**(4): p. 318-327.
38. McMillan, M., H.S. Marshall, and P. Richmond, *4CMenB vaccine and its role in preventing transmission and inducing herd immunity.* Expert Review of Vaccines, 2022. **21**(1): p. 103-114.
39. Zane, G.K., et al., *High Incidence and Duration of Antibiotic Use Among a Cohort of Men Who Have Sex With Men in Seattle, Washington.* Open Forum Infectious Diseases, 2025. **12**(2): p. ofaf051.
40. Goytia, M. and C.B. Wadsworth, *Canary in the Coal Mine: How Resistance Surveillance in Commensals Could Help Curb the Spread of AMR in Pathogenic Neisseria.* mBio, 2022. **13**(5).
41. Harris, P.A., et al., *The REDCap consortium: Building an international community of software platform partners.* Journal of Biomedical Informatics, 2019. **95**: p. 103208.
42. Bankevich, A., et al., *SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing.* Journal of Computational Biology, 2012. **19**(5): p. 455-477.
43. Jolley, K.A., J.E. Bray, and M.C.J. Maiden, *Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications.* Wellcome Open Research, 2018. **3**: p. 124.
44. Bennett, J.S., et al., *The Genus Neisseria*, in *The Prokaryotes: Alphaproteobacteria and Betaproteobacteria*, E. Rosenberg, et al., Editors. 2014, Springer Berlin Heidelberg: Berlin, Heidelberg. p. 881-900.
45. Rodrigues, C.M.C., et al., *Typing complex meningococcal vaccines to understand diversity and population structure of key vaccine antigens.* Wellcome Open Research, 2019. **3**: p. 151.
46. Zankari, E., et al., *Identification of acquired antimicrobial resistance genes.* Journal of Antimicrobial Chemotherapy, 2012. **67**(11): p. 2640-2644.
47. Kumar, S., et al., *MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms.* Molecular Biology and Evolution, 2018. **35**(6): p. 1547-1549.
48. Edgar, R.C., *MUSCLE: multiple sequence alignment with high accuracy and high throughput.* Nucleic Acids Research, 2004. **32**(5): p. 1792-1797.
49. Carver, T.J., et al., *ACT: the Artemis Comparison Tool.* Bioinformatics, 2005. **21**(16): p. 3422-3.
50. EUCAST, E.C.o.A.S.T.-. *Clinical Breakpoints v 15.0*. 2025; Available from: https://www.eucast.org/bacteria/clinical-breakpoints-and-interpretation/clinical-breakpoint-tables/.
51. Willerton, L., et al., *Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19).* PLOS ONE, 2021. **16**(11): p. e0260677.
52. Mauffrey, F., et al., *Impact of mutations in the mtrR, rpdIVD and rrl genes on azithromycin resistance in Neisseria gonorrhoeae.* PLoS One, 2024. **19**(7): p. e0306695.

53. Lex, A., et al., *UpSet: Visualization of Intersecting Sets.* IEEE Trans Vis Comput Graph, 2014. **20**(12): p. 1983-92.
54. Textor J, v.d.Z.B., Gilthorpe MS, Liskiewicz M, Ellison GT, *Robust causal inference using directed acyclic graphs: the R package 'dagitty'.* International Journal of Epidemiology, 2016. **45**(6): p. 1887-1894.
55. Barrett, M., *ggdag: Analyze and Create Elegant Directed Acyclic Graphs*. 2025.
56. Wickham, H., *ggplot2: Elegant graphics for data analysis. 2nd ed. 2016. 260 p. (Use R!).* 2016, Springer Cham: Springer International Publishing : Imprint: Springer 2016. p. 260.
57. Iannone R, R., O *DiagrammeR: Graph/Network Visualization*. 2025.
58. Bazan, J.A., et al., *Large Cluster of Neisseria meningitidis Urethritis in Columbus, Ohio, 2015.* Clinical Infectious Diseases, 2017. **65**(1): p. 92-99.
59. Deghmane, A.E., E. Hong, and M.K. Taha, *Recent Evolution of Susceptibility to Beta-Lactams in Neisseria meningitidis.* Antibiotics (Basel), 2023. **12**(6).
60. Unitt, A., M. Maiden, and O. Harrison, *Characterizing the diversity and commensal origins of penA mosaicism in the genus Neisseria.* Microbial Genomics, 2024. **10**(2).
61. Chen, M., et al., *Meningococcal Quinolone Resistance Originated from Several Commensal Neisseria Species.* Antimicrobial Agents and Chemotherapy, 2020. **64**(2).
62. Unemo, M., C. Del Rio, and W.M. Shafer, *Antimicrobial Resistance Expressed by Neisseria gonorrhoeae : A Major Global Public Health Problem in the 21st Century.* Microbiology Spectrum, 2016. **4**(3): p. 213-237.
63. Jorgensen, J.H., S.A. Crawford, and K.R. Fiebelkorn, *Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents.* Journal of Clinical Microbiology, 2005. **43**(7): p. 3162-71.
64. Tettelin, H., et al., *Complete genome sequence of Neisseria meningitidis serogroup B strain MC58.* Science, 2000. **287**(5459): p. 1809-15.